Inside Sanofi's $470M acquisition of Vigil Neuroscience

The latest stories trending on MedCity News.

Editor's Pick

Top Story Sanofi's Neuro Pipeline Expands to Alzheimer's with $470M Vigil Neuroscience Acquisition The Alzheimer's disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health. Sponsored Attention Data Scientists and Clinicians! Presented by Society of Critical Care Medicine Address real-world critical care issues and improve patient care at the Society of Critical Care Medicine's Datathon. Attend July 19-20 near Chicago to collaborate and revolutionize healthcare with some of the most talented and innovative clinical and data professionals. Sponsorship opportunities are available. Register now.

Featured News

PHTI: Digital Mental Health Solutions Work, But Can Be Costly Virtual solutions for depression and anxiety can lead to clinically meaningful outcomes, but certain pricing models may increase costs for employers and health plans, according to the Peterson Health Technology Institute. GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that's driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year. Who Won MedCity INVEST Pitch Perfect? Startup finalists competed in four tracks: biopharma; devices and diagnostics; health tech aimed at consumers and self-insured employers; and health tech aimed at payers and providers. Investor judges in each track selected the winners. Hidden in Plain Sight: How Existing Hospital Technology Can Prevent Workplace Violence Beyond the human cost, workplace violence carries significant economic consequences for healthcare institutions. Addressing this issue through virtual technology represents not just an ethical imperative but a financial one. Healthcare Price Transparency is More Than Showing a Price Tag As an industry, we can and must do more. To be truly actionable, prices must be easily accessible, understandable, and patients need to be actively engaged to act on that information.

Video   Why One Health System Exec Is Bullish on Clinical AI People often come to FJ Campbell, chief medical officer of Ardent Health, with concerns about integrating AI into clinical models. When they do, he reminds them that AI is now a necessary part of healthcare delivery, especially as the country battles sweeping shortages of doctors and nurses. "We're not going to have enough physicians. We're not going to have enough nurses. I'm not afraid of [AI] because it's actually improving what we can do to load balance the workflows for our nurses, to bring specialty care to our rural hospitals, and therefore load balance patients across an entire community," Campbell stated. He highlighted that AI can do a good job of reducing clinician burnout, which is important for workforce retention.

Sponsored The 4 Best Places to Buy Affordable Spectrometers for Lab Use Presented by OceanOptics Equip your laboratory with cost-effective instruments. Explore the top four companies for affordable spectrometers. Learn More

Resources

MedCity Pivot: How Veradigm Aims to Close the Information Gap Megan Zakrewsky, vice president of product at Veradigm talks about how the company is utilizing tech among providers, payers and patients. Watch now!

MedCity News • PO Box 901 • New York, NY unsubscribe